Published in Nucleic Acid Ther on January 16, 2015
Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell (1987) 20.27
Amino acid-base interactions: a three-dimensional analysis of protein-DNA interactions at an atomic level. Nucleic Acids Res (2001) 7.27
The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem (1994) 6.04
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell (1993) 5.37
Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem (2003) 3.67
SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet (1998) 3.51
Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res (2010) 3.40
An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat (2000) 2.71
Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol (2006) 2.41
Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys (2011) 2.34
Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol (1994) 2.02
Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet (2003) 1.88
Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol (1994) 1.81
Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J (2007) 1.71
Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem (2001) 1.53
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids (2012) 1.41
Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res (2011) 1.35
Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum Mol Genet (2009) 1.30
In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res (1997) 1.28
Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim Biophys Acta (2005) 1.27
Cell-penetrating peptides--a brief introduction. Biochim Biophys Acta (2006) 1.24
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J (2007) 1.20
Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc Chem Res (2011) 1.18
Targeting RNA splicing for disease therapy. Wiley Interdiscip Rev RNA (2013) 1.17
Spinal muscular atrophy: from gene discovery to clinical trials. Ann Hum Genet (2013) 1.15
Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli. Antimicrob Agents Chemother (2005) 1.15
A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release (2008) 1.10
SMN gene deletion in variant of infantile spinal muscular atrophy. Lancet (1995) 1.05
Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation. Gene Ther (2004) 1.02
Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. J Control Release (2009) 1.01
Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Res (2008) 1.00
Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol Ther (2009) 0.98
PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res (2011) 0.97
Peptide nucleic acid (PNA) cell penetrating peptide (CPP) conjugates as carriers for cellular delivery of antisense oligomers. Artif DNA PNA XNA (2012) 0.96
Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons. RNA (2006) 0.96
Genetics of neuromuscular disorders. Crit Rev Clin Lab Sci (2012) 0.93
Spinal muscular atrophy: an update on therapeutic progress. Biochim Biophys Acta (2013) 0.93
Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol Pharm (2011) 0.91
Targeting RNA-splicing for SMA treatment. Mol Cells (2012) 0.91
Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy. Mol Ther Nucleic Acids (2012) 0.89
Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy. Biomed Res Int (2013) 0.88
Synthesis and splice-redirecting activity of branched, arginine-rich peptide dendrimer conjugates of peptide nucleic acid oligonucleotides. Bioconjug Chem (2010) 0.87
Cell-penetrating peptides: A tool for effective delivery in gene-targeted therapies. IUBMB Life (2014) 0.87
Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene. Mol Ther (2013) 0.86
Peptide-based delivery of steric-block PNA oligonucleotides. Methods Mol Biol (2009) 0.83
Agammaglobulinemia: causative mutations and their implications for novel therapies. Expert Rev Clin Immunol (2013) 0.83
Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy. Discov Med (2012) 0.83
Nanomolar cellular antisense activity of peptide nucleic acid (PNA) cholic acid ("umbrella") and cholesterol conjugates delivered by cationic lipids. Bioconjug Chem (2012) 0.83
Differential endosomal pathways for radically modified peptide vectors. Bioconjug Chem (2013) 0.82
Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo. Org Biomol Chem (2013) 0.80
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J Clin Invest (2014) 0.80
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 9.68
Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol (2009) 5.35
Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov (2013) 4.35
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis (2011) 2.32
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev (2009) 2.30
Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet (2012) 2.13
miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA (2007) 1.90
Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov (2011) 1.89
Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy. Nat Med (2013) 1.89
Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc (2012) 1.70
Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet (2008) 1.69
Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther (2007) 1.67
Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev (2005) 1.56
BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat (2006) 1.55
The transcriptional regulator PLZF induces the development of CD44 high memory phenotype T cells. Proc Natl Acad Sci U S A (2008) 1.54
Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol Ther Nucleic Acids (2012) 1.53
Cell-penetrating peptides: design, synthesis, and applications. ACS Nano (2014) 1.52
Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res (2008) 1.52
Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med (2002) 1.48
Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev (2007) 1.47
The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol (2008) 1.47
Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res (2005) 1.44
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids (2012) 1.41
Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res (2010) 1.41
Modulating the expression of disease genes with RNA-based therapy. PLoS Genet (2007) 1.38
Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J Control Release (2005) 1.38
RNA-targeted splice-correction therapy for neuromuscular disease. Brain (2010) 1.36
Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res (2011) 1.35
A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet (2009) 1.34
Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther (2011) 1.32
Genetic therapies for RNA mis-splicing diseases. Trends Genet (2011) 1.31
Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res (2007) 1.28
Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides. Nucleic Acids Res (2005) 1.27
Penetration without cells: membrane translocation of cell-penetrating peptides in the model giant plasma membrane vesicles. J Control Release (2011) 1.26
RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol Dis (2006) 1.22
Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J Control Release (2013) 1.21
Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J Control Release (2011) 1.21
Localization of double-stranded small interfering RNA to cytoplasmic processing bodies is Ago2 dependent and results in up-regulation of GW182 and Argonaute-2. Mol Biol Cell (2008) 1.20
The biogenesis and characterization of mammalian microRNAs of mirtron origin. Nucleic Acids Res (2011) 1.20
Novel RNA-based strategies for therapeutic gene silencing. Mol Ther (2010) 1.20
Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum Mol Genet (2010) 1.19
Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev (2012) 1.17
Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol (2008) 1.15
Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scattering. EMBO J (2003) 1.13
DNA cage delivery to mammalian cells. ACS Nano (2011) 1.13
Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB J (2003) 1.12
Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy. Biochem Biophys Res Commun (2009) 1.12
The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J (2008) 1.11
A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release (2008) 1.10
MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol Biosyst (2006) 1.10
Exosomes and the emerging field of exosome-based gene therapy. Curr Gene Ther (2012) 1.10
Insights into the cellular trafficking of splice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides. J Control Release (2011) 1.09
Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood (2008) 1.08
Quantitatively determined uptake of cell-penetrating peptides in non-mammalian cells with an evaluation of degradation and antimicrobial effects. Peptides (2006) 1.07
Biological activity and biotechnological aspects of peptide nucleic acid. Adv Genet (2006) 1.07
Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover. Nucleic Acids Res (2013) 1.05
MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection. RNA (2011) 1.02
RNA splicing: disease and therapy. Brief Funct Genomics (2011) 1.02
Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. J Control Release (2009) 1.01
A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther (2013) 1.00
Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv (2012) 1.00
Choosing CCR5 or Rev siRNA in HIV-1. Nat Biotechnol (2003) 1.00
Synthesis of peptide-oligonucleotide conjugates with single and multiple peptides attached to 2'-aldehydes through thiazolidine, oxime, and hydrazine linkages. Bioconjug Chem (2002) 1.00
Chemical structure requirements and cellular targeting of microRNA-122 by peptide nucleic acids anti-miRs. Nucleic Acids Res (2011) 1.00
Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res (2011) 1.00
Multiple isoforms of the KC1 cotransporter are expressed in sickle and normal erythroid cells. Exp Hematol (2005) 0.99
Apolar surface area determines the efficiency of translocon-mediated membrane-protein integration into the endoplasmic reticulum. Proc Natl Acad Sci U S A (2011) 0.99
Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther (2010) 0.98
Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochim Biophys Acta (2009) 0.98
Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS One (2009) 0.98
Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: a cohort study. Mol Immunol (2009) 0.97
Functional interaction of caveolin-1 with Bruton's tyrosine kinase and Bmx. J Biol Chem (2001) 0.97
PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res (2011) 0.97